Back to Trials
NCT07196501PHASE3Recruiting

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Biosciences

Start Date

8/18/2025

Completion Date

7/1/2028

Summary

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

Eligibility Criteria

Age Range: 18 years to No maximum

Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode. Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Interventions

DRUG

NBI-1065845

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Major Depressive Disorder

Locations

Neurocrine Clinical Site

Oceanside, California 92056

United States

Neurocrine Clinical Site

Orange, California 92868

United States

Neurocrine Clinical Site

San Jose, California 95124

United States

Neurocrine Clinical Site

New Haven, Connecticut 06520

United States

Neurocrine Clinical Site

Miami Gardens, Florida 33014

United States

Neurocrine Clinical Site

Orlando, Florida 32803

United States

Neurocrine Clinical Site

Palm Bay, Florida 32905

United States

Neurocrine Clinical Site

Tampa, Florida 33629

United States

Neurocrine Clinical Site

Iowa City, Iowa 52242

United States

Neurocrine Clinical Site

Marrero, Louisiana 70072

United States

Neurocrine Clinical Site

O'Fallon, Missouri 63368

United States

Neurocrine Clinical Site

Albuquerque, New Mexico 87109

United States

Neurocrine Clinical Site

Glen Oaks, New York 11004

United States

Neurocrine Clinical Site

Charlotte, North Carolina 28211

United States

Neurocrine Clinical Site

Edmond, Oklahoma 73013

United States

Neurocrine Clinical Site

Oklahoma City, Oklahoma 73112

United States

Neurocrine Clinical Site

Philadelphia, Pennsylvania 19104

United States

Neurocrine Clinical Site

Austin, Texas 78712

United States

Neurocrine Clinical Site

Bellaire, Texas 77401

United States

Neurocrine Clinical Site

Friendswood, Texas 77546

United States

Neurocrine Clinical Site

Stafford, Texas 77477

United States

Neurocrine Clinical Site

Wichita Falls, Texas 76309

United States

Neurocrine Clinical Site

Draper, Utah 84020

United States

Neurocrine Clinical Site

Roanoke, Virginia 24018

United States

Neurocrine Clinical Site

Carlton, Victoria 3053

Australia

Neurocrine Clinical Site

Melbourne, Victoria 3004

Australia

Neurocrine Clinical Site

Parkville, Victoria 3050

Australia

Neurocrine Clinical Site

Sofia, 1303

Bulgaria

Neurocrine Clinical Site

Sofia, 1408

Bulgaria

Neurocrine Clinical Site

Sofia, 1510

Bulgaria

Neurocrine Clinical Site

Sofia, 1680

Bulgaria

Neurocrine Clinical Site

Calgary, Alberta T2N 2T9

Canada

Neurocrine Clinical Site

North Vancouver, British Columbia V7P 2T4

Canada

Neurocrine Clinical Site

Kingston, Ontario K7L 4X3

Canada

Neurocrine Clinical Site

Sherbrooke, Quebec J1L 0H8

Canada

Neurocrine Clinical Site

Toronto, M5H 1A1

Canada

Neurocrine Clinical Site

Tallinn, 10138

Estonia

Neurocrine Clinical Site

Tallinn, 11315

Estonia

Neurocrine Clinical Site

Tartu, 50417

Estonia

Neurocrine Clinical Site

Milan, 20127

Italy

Neurocrine Clinical Site

Roma, 168

Italy

Neurocrine Clinical Site

Rome, 168

Italy

Neurocrine Clinical Site

Torino, 10126

Italy

Neurocrine Clinical Site

Bialystok, 15-879

Poland

Neurocrine Clinical Site

Bydgoszcz, 85-794

Poland

Neurocrine Clinical Site

Gdansk, 80-283

Poland

Neurocrine Clinical Site

Belgrade, 11000

Serbia

Neurocrine Clinical Site

Kovin, 26220

Serbia

Neurocrine Clinical Site

Kragujevac, 34000

Serbia

Neurocrine Clinical Site

Ansan-si, Gyeonggi-do 15355

South Korea

Neurocrine Clinical Site

Seoul, 02841

South Korea

Neurocrine Clinical Site

Seoul, 06351

South Korea

Neurocrine Clinical Site

Seoul, 3181

South Korea

Neurocrine Clinical Site

Alcorcón, Madrid 28922

Spain

Neurocrine Clinical Site

Barcelona, 08025

Spain

Neurocrine Clinical Site

Barcelona, 08035

Spain

Neurocrine Clinical Site

Keelung, 204

Taiwan

Neurocrine Clinical Site

Taipei, 10449

Taiwan

Neurocrine Clinical Site

Taipei, 110

Taiwan

Neurocrine Clinical Site

Taipei, 11217

Taiwan